Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc.'s SEC filings document its foreign-private-issuer reporting for a clinical-stage biotechnology company developing antibody-based cancer immunotherapies. Form 6-K reports furnish clinical-data releases for muzastotug, regulatory updates for MSS colorectal cancer development, full-year financial results, business updates and notices of scientific presentations.
The filings also cover capital-structure and financing matters, including ADS offerings, underwriting agreements and the ADS-to-ordinary-share relationship. Other disclosures include licensing and collaboration agreements using SAFEbody technology, share-based compensation and equity accounts, governance updates, clinical development risks and exhibits furnished under Exchange Act reporting rules.
Adagene Inc., a Cayman Islands holding company with substantive operations in China and the U.S., files its annual report and reports 59,231,993 ordinary shares outstanding as of December 31, 2025. Investors hold equity in the Cayman parent, not directly in its PRC or U.S. subsidiaries.
The report emphasizes extensive PRC-related risks, including government authority to influence or restrict operations, evolving rules on offshore offerings, cybersecurity and data security, and possible limits on cross-border transfers of scientific and personal data. It also details historical PCAOB inspection limits and the risk of potential HFCAA-driven delisting if future inspections lapse.
Adagene highlights complex tax, foreign exchange and corporate law exposure in China, including potential PRC resident enterprise classification, withholding taxes on dividends and share transfers, M&A and foreign investment reviews, and SAFE registration requirements for offshore structures and employee equity plans. The company notes that changes in U.S.–China trade and investment policies could further affect funding, collaborations and its industry supply chain.
Adagene Inc. Schedule 13G filing reports that Jorey Chernett beneficially owned 2,389,060 Ordinary shares as of the close of business on March 17, 2026, representing 5.1% of the class based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025, per the issuer's prospectus.
The cover disclosure notes the CUSIP 005329107 is assigned to the issuer's ADSs quoted on NASDAQ under the symbol ADAG, and that each ADS represents one and one quarter Ordinary Share. The filing is a beneficial ownership report by the reporting person, signed on March 18, 2026.
Adagene Inc. Chief Strategy Officer Chane-Du Mickael Yannick filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 279,506 Adagene ordinary shares directly and 188,019 shares indirectly through OT Healthcare Fund I, LLC.
The filing also lists incentive stock options for 400,000 ordinary shares at an exercise price of 1.3760 per share expiring on May 13, 2035, and 400,000 performance-based options at 2.0320 per share expiring on February 5, 2036. In addition, he has indirect warrants for 250,000 shares expiring on July 3, 2028 and 250,000 shares expiring on September 2, 2028 through OT Bio Advisory, LLC.
Adagene Inc. director and Chief Financial Officer Tam Man Kin filed an initial ownership report showing direct holdings in ordinary shares and equity awards. He reports 116,583 Ordinary Shares held directly, plus 37,500 Restricted Stock Units granted under the 2021 Performance Incentive Plan, scheduled to vest in three equal installments on July 23, 2026, July 23, 2027, and July 23, 2028.
He also holds several nonqualified stock options over Adagene ordinary shares with exercise prices ranging from $1.04 to $2.032 per share and expiration dates between 2030 and 2036. Footnotes indicate which grants are time-based or performance-based and which portions are already vested and exercisable.
Adagene Inc. Chief Executive Officer Peter Luo filed an initial statement of beneficial ownership, detailing his existing equity positions in the company. The filing lists direct holdings of ordinary shares, multiple incentive stock options to acquire ordinary shares at exercise prices ranging from $1.04 to $13.85 with expirations between 2031 and 2036, and restricted stock units granted under Adagene’s equity plans. It also discloses additional options, RSUs, and ordinary shares held indirectly through his spouse. The document reports holdings only and does not show any purchases or sales.
Adagene Inc. executive director of human resources Zhou Ling filed an initial Form 3 reporting existing equity holdings in the company. The filing shows direct ownership of 2,969 ordinary shares, 9,375 restricted stock units and multiple nonqualified stock options over ordinary shares.
The RSUs were granted under Adagene’s 2021 Performance Incentive Plan, with 3,125 units scheduled to vest on each of 7/23/2026, 7/23/2027 and 7/23/2028. Option positions include fully vested grants over 25,000, 3,125 and 1,250 shares, plus additional time-based options ranging from 20,000 to 35,000 underlying shares with exercise prices between 1.0400 and 5.6000 per share and expirations from 2030 through 2036.
Adagene Inc. director Zhu Li filed an initial statement of beneficial ownership, detailing nonqualified stock options over the company’s ordinary shares. The filing shows options covering 20,000 shares at an exercise price of $1.1500 per share that are fully vested and exercisable under the Adagene Inc. 2021 Performance Incentive Plan.
It also lists options over 25,000 shares at $1.5500 per share granted on December 24, 2024, which vest 25% on each of the first four anniversaries of the grant date; 6,250 of these shares are vested and exercisable. A further 25,000-share option at $2.0320 per share was granted on February 5, 2026, becoming exercisable as to 25% of the shares on each of the first four anniversaries of that grant.
Adagene Inc. executive director of finance Gu Chunfang filed an initial Form 3 showing existing equity interests in the company. The filing lists direct holdings of stock options over multiple blocks of Ordinary Shares, with exercise prices ranging from 1.04 to 5.60 per share and expirations between 2029 and 2036. Gu also holds 7,045 Ordinary Shares directly and 23,438 Restricted Stock Units under the Adagene Inc. 2021 Performance Incentive Plan. According to the vesting schedule, 7,813 RSUs are scheduled to vest on each of 7/23/2026, 7/23/2027, and 7/23/2028, while several option grants are already fully vested and exercisable.
Adagene Inc. director Andy Yiu Leung Cheung filed an initial ownership report showing he holds several nonqualified stock options over the company’s ordinary shares. These options cover 20,000 shares at an exercise price of $11.2000 per share expiring on June 18, 2031, 25,000 shares at $1.5500 per share expiring on December 24, 2034, and 25,000 shares at $2.0320 per share expiring on February 5, 2036. The filing notes that 20,000 option shares are fully vested and exercisable, while 6,250 shares from the 25,000-share grant dated December 24, 2024 are currently vested, with the remainder of that grant and the latest 25,000-share grant scheduled to vest in 25% annual installments.
Adagene Inc. executive Zhao Qinghai, the Chief Manufacturing Officer, filed an initial statement of beneficial ownership showing a mix of ordinary shares, stock options, and restricted stock units in the company.
The filing lists several incentive and performance-based stock options over ordinary shares with exercise prices ranging from $1.04 to $5.60 per share and expiration dates between 2030 and 2036. Footnotes explain that some option grants are fully vested and exercisable, while others vest over four years or in two large tranches in 2025 and 2026. Zhao also holds 130,214 ordinary shares directly and 37,500 restricted stock units granted under Adagene’s 2021 Performance Incentive Plan, with 12,500 RSUs scheduled to vest on each of July 23, 2026, July 23, 2027, and July 23, 2028.